These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28429653)

  • 1. Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.
    Cooper JP; Reynolds CP; Cho H; Kang MH
    Exp Biol Med (Maywood); 2017 Jun; 242(11):1178-1184. PubMed ID: 28429653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex.
    Maurer BJ; Kalous O; Yesair DW; Wu X; Janeba J; Maldonado V; Khankaldyyan V; Frgala T; Sun BC; McKee RT; Burgess SW; Shaw WA; Reynolds CP
    Clin Cancer Res; 2007 May; 13(10):3079-86. PubMed ID: 17505011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.
    Maurer BJ; Kang MH; Villablanca JG; Janeba J; Groshen S; Matthay KK; Sondel PM; Maris JM; Jackson HA; Goodarzian F; Shimada H; Czarnecki S; Hasenauer B; Reynolds CP; Marachelian A
    Pediatr Blood Cancer; 2013 Nov; 60(11):1801-8. PubMed ID: 23813912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas.
    Kummar S; Gutierrez ME; Maurer BJ; Reynolds CP; Kang M; Singh H; Crandon S; Murgo AJ; Doroshow JH
    Anticancer Res; 2011 Mar; 31(3):961-6. PubMed ID: 21498721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients.
    Formelli F; Cavadini E; Luksch R; Garaventa A; Appierto V; Persiani S
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):993-8. PubMed ID: 20532509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.
    Lopez-Barcons L; Maurer BJ; Kang MH; Reynolds CP
    Int J Cancer; 2017 Jul; 141(2):405-413. PubMed ID: 28340497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide.
    Formelli F; Cavadini E; Luksch R; Garaventa A; Villani MG; Appierto V; Persiani S
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):655-65. PubMed ID: 18066548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group.
    Villablanca JG; London WB; Naranjo A; McGrady P; Ames MM; Reid JM; McGovern RM; Buhrow SA; Jackson H; Stranzinger E; Kitchen BJ; Sondel PM; Parisi MT; Shulkin B; Yanik GA; Cohn SL; Reynolds CP
    Clin Cancer Res; 2011 Nov; 17(21):6858-66. PubMed ID: 21908574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced anti-neuroblastoma activity of a fenretinide complexed form after intravenous administration.
    Carosio R; Pistoia V; Orienti I; Formelli F; Cavadini E; Mangraviti S; Montaldo PG; Ognio E; Emionite L; Zuccari G
    J Pharm Pharmacol; 2012 Feb; 64(2):228-36. PubMed ID: 22221098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors.
    Thomas JS; El-Khoueiry AB; Maurer BJ; Groshen S; Pinski JK; Cobos E; Gandara DR; Lenz HJ; Kang MH; Reynolds CP; Newman EM
    Cancer Chemother Pharmacol; 2021 Apr; 87(4):525-532. PubMed ID: 33423090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia.
    Song MM; Makena MR; Hindle A; Koneru B; Nguyen TH; Verlekar DU; Cho H; Maurer BJ; Kang MH; Reynolds CP
    Anticancer Drugs; 2019 Feb; 30(2):117-127. PubMed ID: 30272587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709).
    ; Villablanca JG; Krailo MD; Ames MM; Reid JM; Reaman GH; Reynolds CP
    J Clin Oncol; 2006 Jul; 24(21):3423-30. PubMed ID: 16849757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells.
    Orienti I; Salvati V; Sette G; Zucchetti M; Bongiorno-Borbone L; Peschiaroli A; Zolla L; Francescangeli F; Ferrari M; Matteo C; Bello E; Di Virgilio A; Falchi M; De Angelis ML; Baiocchi M; Melino G; De Maria R; Zeuner A; Eramo A
    J Exp Clin Cancer Res; 2019 Aug; 38(1):373. PubMed ID: 31439019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attempts to Improve Lipophilic Drugs' Solubility and Bioavailability: A Focus on Fenretinide.
    Alfei S; Zuccari G
    Pharmaceutics; 2024 Apr; 16(5):. PubMed ID: 38794242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial.
    Mohrbacher AM; Yang AS; Groshen S; Kummar S; Gutierrez ME; Kang MH; Tsao-Wei D; Reynolds CP; Newman EM; Maurer BJ
    Clin Cancer Res; 2017 Aug; 23(16):4550-4555. PubMed ID: 28420721
    [No Abstract]   [Full Text] [Related]  

  • 16. Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts.
    Chen NE; Maldonado NV; Khankaldyyan V; Shimada H; Song MM; Maurer BJ; Reynolds CP
    Mol Cancer Ther; 2016 Nov; 15(11):2653-2664. PubMed ID: 27530131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma.
    Di Paolo D; Pastorino F; Zuccari G; Caffa I; Loi M; Marimpietri D; Brignole C; Perri P; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M; Pagnan G
    J Control Release; 2013 Sep; 170(3):445-51. PubMed ID: 23792118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma.
    Garaventa A; Luksch R; Lo Piccolo MS; Cavadini E; Montaldo PG; Pizzitola MR; Boni L; Ponzoni M; Decensi A; De Bernardi B; Bellani FF; Formelli F
    Clin Cancer Res; 2003 Jun; 9(6):2032-9. PubMed ID: 12796365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fenretinide-polyvinylalcohol conjugates: new systems allowing fenretinide intravenous administration.
    Orienti I; Zuccari G; Bergamante V; Carosio R; Gotti R; Cilli M; Montaldo PG
    Biomacromolecules; 2007 Oct; 8(10):3258-62. PubMed ID: 17883277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.
    Villani MG; Appierto V; Cavadini E; Bettiga A; Prinetti A; Clagett-Dame M; Curley RW; Formelli F
    Cancer Res; 2006 Mar; 66(6):3238-47. PubMed ID: 16540676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.